An interventional study of robotic-assisted surgery and Open Surgery in Papillary Thyroid Carcinoma and Lymphatic Metastasis, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.
Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is one of 10 that started in 2024, is one of 14 with no phase, reaches primary completion later than 24 of the 24 other live ones, and was the 28th registered.
187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.
Browse Thyroid Cancer, Papillary studies →24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:
Ming-an Yu · Sites in China
Ages 16–60
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Second Affiliated Hospital of Xi'an Jiaotong University · Sites in China
Ages 16–80
Shanghai 6th People's Hospital · Sites in China
Chinese PLA General Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2015; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 876 is above the median of 41 across 114 interventional studies indexed under Thyroid Cancer, Papillary.
Median enrollment 170 across the 21 interventional studies, 541 across the 19 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University has 6 studies filed under Thyroid Cancer, Papillary — fewer than ten, so there is no comparison to draw.
5 of the studies in Thyroid Cancer, Papillary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357571Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPreoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound | 2026-12-31 |
| NCT06316895Chinese PLA General HospitalThe Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma | 2027-04-01 |
| NCT06804863West China HospitalRegret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer | 2027-05-01 |
| NCT06610604Ming-an YuHealth-Related Quality of Life and Emotions in Patients with Thyroid Nodules | 2027-06 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Thyroid Cancer, Papillary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Thyroid cancer is one of the most common malignant tumors in women, ranking seventh in the United States and fourth in China. Papillary thyroid carcinoma is the most common pathological type (about 85% to 90% of thyroid cancers), and lateral cervical lymph node metastasis can reach 0.6-37.5% at diagnosis. For papillary thyroid cancer with lateral cervical lymph node metastasis, the 2015 ATA Guidelines in the United States recommend surgical resection and neck lymph node dissection as the primary treatment. Traditional cervical lymph node dissection often leaves obvious scars in the neck, which seriously affects the postoperative quality of life of patients. The previous studies have shown that endoscopy-assisted surgery with external cervical approach can achieve oncologic effects similar to traditional open surgery in the treatment of N1b papillary thyroid cancer, and can obtain better aesthetic results. However, endoscopic surgery still has some shortcomings, such as poor exposure of some surgical areas and difficult operation. Since November 2016, the investigators tried to apply modified transaxillary robotic-assisted surgery technology to the treatment of thyroid papillary carcinoma in China. The preliminary study included 30 patients, and the results showed that robot-assisted surgery via combined transaxillary-retroaural approach in the treatment of N1b papillary thyroid carcinoma achieved a good oncologic effect (5-year overall survival rate was 100.0%). As the surgical techniques improved, now the investigators can complete robotic-assisted lateral neck lymph node dissection via single-incision transaxillary approach. However, there is still a lack of high-quality evidence on the long-term oncologic outcome and quality of life of this procedure. In this study, a prospective, multi-center, randomized controlled study was conducted to compare the safety, long-term oncologic outcomes and postoperative quality of life of the robot-assisted surgery via single-incision transaxillary approach and open surgery in the treatment of N1b papillary thyroid cancer, which may provide an alternative for the patients with N1b papillary thyroid cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: robotic-assisted surgery
conventional treatment
Procedure: Open Surgery
robotic-assisted surgery via single-incision transaxillary approach
conventional open surgery
the disease-free survival rate
The 5-year survival rate without a functional, structural, or biological event
Time frame: 60 months
Postoperative quality of life:36-Item Short-Form Survey
The quality of life is assessed by 36-Item Short-Form Survey (SF-36) 1 year after surgery, and the differences in physical and physiological dimensions between the two groups were compared. The higher scores mean a better outcome.
Time frame: 12 months
Overall survival(OS)
The time from randomization to death from any cause
Time frame: 60 months
The dynamic change trend of shoulder function
Shoulder function is assessed using arm abduction test (0-5) to explore the dynamic change. The higher scores mean a better outcome.
Time frame: 60 months
The dynamic change trend of the postoperative quality of life
The postoperative quality of life is assessed using 36-Item Short-Form Survey to explore the dynamic change. The higher scores mean a better outcome.
Time frame: 60 months
The dynamic change of swallowing function
Swallowing function is assessed using Swallowing Impairment Index 6 (0-24) to explore the dynamic change. The higher scores mean a worse outcome.
Time frame: 60 months
The dynamic change trend of neck function
Neck function is assessed using Ten-item Neck Dissection Impairment Index (0-100) to explore the dynamic change. The higher scores mean a better outcome.
Time frame: 60 months
The dynamic change trend of aesthetic satisfaction
Aesthetic satisfaction is assessed using verbal response scale (0-10) to explore the dynamic change. The higher scores mean a better outcome.
Time frame: 60 months
The dynamic change trend of voice function
Voice function is assessed using Voice Handicap Index 10 (0-40) to explore the dynamic change. The higher scores mean a worse outcome.
Time frame: 60 months
Started Sep 2024 (actual). Primary completion is estimated for Dec 2033, 111 months after the start.
Of 26 interventional studies with no phase under Thyroid Cancer, Papillary, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 71. This study's planned 111 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →